Please Note: MBL International will be shutting down its operations effective December 31, 2024. Distribution of MBL products in the United States will be transferred to Cosmo Bio US on January 1st while European Distributors will remain unchanged. For any US inquiries regarding orders or support during this transition, reach out to Cosmo Bio: https://www.cosmobiousa.com/. For Non-US inquiries reach out to MBL in Japan: https://www.mblbio.com/.

Select Page

JAK2 Rabbit mAb

CNA19629S
Antibody
100 µl

THIS ITEM HAS BEEN DISCONTINUED

DATA SHEET

TargetJAK2
Product TypeAntibody
ApplicationIP, WB
ClonalityMonoclonal
IsotypeIgG
ImmunogenA synthetic peptide corresponding to a sequence within amino acids 1033-1132 of human JAK2 (O60674).
Host SpeciesRabbit
Species ReactivityHuman, Mouse
FormulationPBS with 0.02% sodium azide,0.05% BSA,50% glycerol
Research AreaCancer, Immunology, Epigenetics
Description/Background

This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

ProtocolsIP, WB
Molecular Weight131kDa
PurityAffinity purification
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
CNA19629S
Antibody
100 µl

SIGN UP